Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combining SARS-CoV-2 Proofreading Exonuclease and RNA-Dependent RNA Polymerase Inhibitors as a Strategy to Combat COVID-19: A High-Throughput in silico Screening

20 Jul 2021

Abstract excerpt

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people worldwide. Currently, many clinical trials in search of effective COVID-19 drugs are underway. Viral RNA-dependent RNA polymerase (RdRp) remains the target of choice for prophylactic or curative treatment of COVID-19. Nucleoside analogs are the most promising RdRp inhibitors and have shown effectivenessin vitro, as well...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34354677
DOI: 10.3389/fmicb.2021.647693

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combining SARS-CoV-2 Proofreading Exonuclease and RNA-Dependent RNA Polymerase Inhibitors as a Strategy to Combat COVID-19: A High-Throughput in silico ScreeningPMID 34354677Read ↗

The NSP14/NSP10 RNA repair complex as a Pan-coronavirus therapeutic targetSemantic proximity Read ↗

SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19Semantic proximity Read ↗

Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.Semantic proximity Read ↗

Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoNSemantic proximity Read ↗

An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challengesSemantic proximity Read ↗

Recent advances in small-molecular therapeutics for COVID-19Semantic proximity Read ↗

Identification of recurrent mutations in exonuclease (nsp14); a potential drug target in SARS-CoV-2.Semantic proximity Read ↗

Characterization of the SARS-CoV-2 ExoN (nsp14ExoN–nsp10) complex: implications for its role in viral genome stability and inhibitor identificationSemantic proximity Read ↗

Coronavirus genomic nsp14‐ExoN, structure, role, mechanism, and potential application as a drug targetSemantic proximity Read ↗

A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymeraseSemantic proximity Read ↗

In silico analysis of RNA-dependent RNA polymerase of the SARS-CoV-2 and potentiality of the pre-existing drugsSemantic proximity Read ↗

Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting virusesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.